Kent Imaging Revolutionizes Perfusion Imaging with Their FDA Cleared KD203
CALGARY, Oct. 19, 2017 /CNW/ - Kent Imaging, a leading provider of near infrared imaging solutions, announced today that the U.S. Food and Drug Administration (FDA) has cleared their multispectral Medical Imaging Device (KD203).
Kent's device is the next step in perfusion imaging by directly showing tissue oxygenation. The KD203 provides insight into the availability of oxygenated blood in tissue, which enables accurate diagnosis, improved treatment planning and effective patient monitoring.
"Using the Kent camera, we can quantify perfusion directly by determining the ratio of oxygenated to deoxygenated hemoglobin", said Dr. Adam Landsman, DPM, PhD, Chief of Division of Podiatric Surgery at the Cambridge Health Alliance (Harvard Medical School). "Furthermore, because the data can be collected in less than a second, the device can help to quantify the effect of our treatments, and allow us to easily monitor the patient's condition on a regular basis."
"We are very excited about obtaining Class II FDA clearance for our handheld device", said Pierre Lemire, CEO of Kent Imaging. "Our low cost and easy to use device helps physicians to determine the most effective treatment plans which provides them a means of reducing recovery times and patient discomfort."
Features of Kent's KD203:
Instant wound assessment
Non-invasive with no injectables or dyes
A means to track patient progress and treatment effectiveness
Provides quantified tissue oxygenation levels
No disruption to existing workflow
Accurate, unlimited imaging and storage
Ease-of-use with minimal training required
Low cost device with no disposables
Lightweight portable handheld device
The KD203 is now available for sale in both the United States and Canada.
About Kent Imaging Inc.
Kent Imaging, located in Calgary, Alberta, Canada, is a leading developer of medical technology, who designs, manufactures and markets imaging technology for wound and surgical care. Kent holds multiple patents in medical technology and continues to provide innovative and advanced diagnostic imaging solutions to aid healthcare systems nationally and internationally. For more information about our company visit us at www.kentimaging.com.
Acadia Pharmaceuticals Inc. today announced that two oral presentations featuring DAYBUEtm (trofinetide) findings in Rett syndrome will be presented at the American Academy of Neurology (AAN) 2024 annual meeting, being held this week in Denver, CO....
DiaMedica Therapeutics Inc. , a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today announced the first patient being dosed in DiaMedica's relaunch of its pivotal...
Jazz Pharmaceuticals plc today announced that it will report its 2024 first quarter financial results on Wednesday, May 1, 2024, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30...
In response to the 2024 Federal Budget, Community Food Centres Canada (CFCC) expresses concern over the budget's failure to tackle the pervasive issue of food insecurity in Canada. With 1 in 5 people in Canada living with food insecurity, the federal...
Rallybio Corporation , a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced the presentation of results from a...
Biohaven Ltd. , a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience and oncology, today announced that it has commenced an...